Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia
Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study is mainly assessing the safety of Revlimid in combination with Ancestim
(recombinant human stem cell factor) in patients with symptomatic myelodysplasia. Of those
two compounds, Revlimid has been shown to be an active drug in myelodysplasia. Clinical
responses will also be assessed.